Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the […]
Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clinically meaningful, placebo adjusted improvements in anxiety measures. Definium Therapeutics shares have rallied strongly, with a 90 day share price return of 66.6% and a year to date share price gain of 195.09%. The 1 year total shareholder re […]
Definium Therapeutics' LSD eased the symptoms of anxiety, the company said Monday as shares took off again.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.
Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
Definium Therapeutics' synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again.
Definium Therapeutics, Inc. (NASDAQ:DFTX) shares rose 20% after the company reported topline results from its Phase 3 Panorama study evaluating DT120 ODT in patients with generalized anxiety disorder.